# Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

> **NCT00012298** · PHASE1,PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 81 (actual)

## Conditions studied

- Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
- Nodal Marginal Zone B-cell Lymphoma
- Recurrent Grade 1 Follicular Lymphoma
- Recurrent Grade 2 Follicular Lymphoma
- Recurrent Grade 3 Follicular Lymphoma
- Recurrent Marginal Zone Lymphoma
- Recurrent Small Lymphocytic Lymphoma
- Splenic Marginal Zone Lymphoma
- Waldenström Macroglobulinemia

## Interventions

- **BIOLOGICAL:** rituximab
- **BIOLOGICAL:** yttrium Y 90 ibritumomab tiuxetan
- **BIOLOGICAL:** indium In 111 ibritumomab tiuxetan
- **BIOLOGICAL:** oprelvekin
- **BIOLOGICAL:** filgrastim

## Key facts

- **NCT ID:** NCT00012298
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2001-04
- **Primary completion:** 2010-04
- **Final completion:** 2010-04
- **Target enrollment:** 81 (ACTUAL)
- **Why stopped:** Trial completed prematurely.
- **Last updated:** 2018-08-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00012298

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00012298, "Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00012298. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*